recombinant plasmin (Grifols/Bausch & Lomb)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant plasmin (Grifols/Bausch & Lomb)
Drug Alias Namedelta [K2-K5] plasminrPlasmin (Grifols/Bausch & Lomb)rPlasmin (Talecris Biotherapeutics/Bausch & Lomb)recombinant plasmin (Talecris Biotherapeutics/Bausch & Lomb)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionCoagulation factor inhibitors
TargetsCoagulation factor
Therapy Area/IndicationsIschemic StrokeVascular DiseasesEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGrifols Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGrifols IncBausch&Lomb Inc
Active IndicationsN/A
Inactive IndicationsIschemic StrokeVascular DiseasesEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A